CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 29 enrolled
Drug / intervention
Pimavanserindrug
Likely dose
Pimavanserin 34 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04292223
NCT04292223Phase 4Completed
CompareCT.gov

A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Inc.·interventional·Posted Mar 3, 2020·Updated Jan 14, 2025

In Brief

A Phase 4 clinical trial evaluating Pimavanserin for Parkinson Disease Psychosis. Completed, enrolled 29 participants across 18 sites.

Detailed Summary

To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease Psychosis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedMar 3, 2020
Enrollment StartFeb 10, 2020
Primary CompletionApr 26, 2022
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.3 years ago

Interventions

Pimavanserindrug

Pimavanserin 34 mg (provided as 1×34 mg capsule), administered orally, once daily for 16 weeks